Education
About Us
Working with TipRanks
Follow Us
In8bio, Inc. (INAB)
:INAB
INAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.14 - $1.74
Previous CloseN/A
Volume363.43K
Average Volume (3M)1.30M
Market Cap
$12.28M
Enterprise Value$14.25M
Total Cash (Recent Filing)$610.00K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.76
Next Earnings
May 08, 2025EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding81,258,766
10 Day Avg. Volume1,043,520
30 Day Avg. Volume1,295,327
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.16
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.50
Forecast
1Y Price Target
$3.07Price Target Upside1946.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
IN8bio News
PremiumCompany Announcements
IN8bio Reports Progress in Cancer Therapies
---
Bulls Say, Bears Say
Bulls Say
Clinical OutcomesINB-100 treated AML patients demonstrate 100% survival and complete remission at a median follow-up of 20.1 months.
Clinical Trial ProgressThe INB-100 treatment has shown benefits beyond existing treatments while maintaining a clean safety profile with no severe side effects reported.
Financial StabilityManagement expects the company's cash reserves to support operations until March 2026, indicating financial stability.
Bears Say
Financial RiskCapital overhang remains the key risk for INAB with approximately $15 million at the end of 3Q24.
Stock DilutionThe price target is lowered to $6 per share due to stock dilution.
Study LimitationsThe data is from an open-arm single center study, which may limit the generalizability of the results.
---
Ownership Overview
29.90% Insiders
2.12% Mutual Funds
26.93% Other Institutional Investors
39.24% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
INAB FAQ
What was In8bio, Inc.’s price range in the past 12 months?
In8bio, Inc. lowest stock price was $0.14 and its highest was $1.74 in the past 12 months.
What is In8bio, Inc.’s market cap?
In8bio, Inc.’s market cap is $12.28M.
When is In8bio, Inc.’s upcoming earnings report date?
In8bio, Inc.’s upcoming earnings report date is May 08, 2025 which is in 31 days.
How were In8bio, Inc.’s earnings last quarter?
In8bio, Inc. released its earnings results on Mar 13, 2025. The company reported -$0.08 earnings per share for the quarter, missing the consensus estimate of -$0.072 by -$0.008.
Is In8bio, Inc. overvalued?
According to Wall Street analysts In8bio, Inc.’s price is currently Undervalued.
Does In8bio, Inc. pay dividends?
In8bio, Inc. does not currently pay dividends.
What is In8bio, Inc.’s EPS estimate?
In8bio, Inc.’s EPS estimate is -0.07.
How many shares outstanding does In8bio, Inc. have?
In8bio, Inc. has 81,258,766 shares outstanding.
What happened to In8bio, Inc.’s price movement after its last earnings report?
In8bio, Inc. reported an EPS of -$0.08 in its last earnings report, missing expectations of -$0.072. Following the earnings report the stock price went down -4.348%.
Which hedge fund is a major shareholder of In8bio, Inc.?
Currently, no hedge funds are holding shares in INAB
---
Company Description
In8bio, Inc.
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
---
INAB Stock 12 Month Forecast
Average Price Target
$3.07
▲(1946.67% Upside)
Technical Analysis
Fate Therapeutics
―
Karyopharm Therapeutics
―
Iovance Biotherapeutics
―
Adaptimmune Therapeutics
―
Allogene Therapeutics
―
Best Analysts Covering INAB
1 Year
1 Year Success Rate
0/17 ratings generated profit
1 Year Average Return
-58.88%
reiterated a buy rating 24 days ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -58.88% per trade.
---